Literature DB >> 3732641

Intravenous omeprazole: effect on 24-hour intragastric pH in duodenal ulcer patients.

T Lind, M Moore, L Olbe.   

Abstract

This study was aimed to identify an intravenous dosage regime of omeprazole which would sufficiently suppress acid secretion to maintain intragastric pH greater than 4 continuously. Thirteen duodenal ulcer patients in remission received omeprazole in daily intravenous doses ranging from 40 to 200 mg. Doses were successively increased as dictated by patient response. The intragastric pH data indicated that omeprazole given in twice or thrice daily regimes in total intravenous amounts of 200, 160 and 160 mg over a consecutive 3-day period markedly inhibited acid secretion and maintained intragastric pH greater than 4 with few and short-term exceptions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732641     DOI: 10.1159/000199314

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  9 in total

1.  Effect of intravenous omeprazole on intragastric pH during intravenous infusion of amino acids.

Authors:  L C Baak; J B Jansen; C B Lamers
Journal:  Dig Dis Sci       Date:  1990-05       Impact factor: 3.199

2.  Stress-related Mucosal Disease.

Authors:  Mitchell J. Spirt
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

3.  Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects.

Authors:  S Teyssen; S T Chari; J Scheid; M V Singer
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

4.  Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study.

Authors:  J Labenz; U Peitz; C Leusing; B Tillenburg; A L Blum; G Börsch
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

Review 5.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

6.  Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.

Authors:  C H Wilder-Smith; H U Bettschen; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

Review 7.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

8.  Pharmacokinetics of intravenous omeprazole in children.

Authors:  E Jacqz-Aigrain; M Bellaich; C Faure; J Andre; P Rohrlich; V Baudouin; J Navarro
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245.

Authors:  J H Wandall
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.